Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13739403 | 0.87 | ALDH1A1 (1.00) | NOTUMALDH1A1NR1H4MAPK1SMN1; SMN2 | |
| SCHEMBL20604296 | 0.86 | NOTUM (1.00) | NOTUMALDH1A1NR1H4SMN1; SMN2MAPT | |
| SCHEMBL28017620 | 0.85 | NOTUM (0.74) | NOTUMALDH1A1NR1H4MAPK1SMN1; SMN2 | |
| SCHEMBL3132883 | 0.84 | NOTUM (1.00) | NOTUMALDH1A1NR1H4 | |
| SCHEMBL1979515 | 0.83 | NOTUM (1.00) | NOTUMALDH1A1NR1H4SMN1; SMN2 | |
| SCHEMBL11457537 | 0.83 | NOTUM (0.70) | NOTUMALDH1A1NR1H4MAPK1SMN1; SMN2 | |
| SCHEMBL14226141 | 0.83 | NOTUM (0.70) | NOTUMALDH1A1MAPK1SMN1; SMN2MAPT | |
| SCHEMBL16403258 | 0.83 | NOTUM (0.70) | NOTUMALDH1A1 | |
| SCHEMBL13740783 | 0.83 | ALDH1A1 (0.72) | NOTUMALDH1A1MAPK1SMN1; SMN2MAPT | |
| SCHEMBL13832765 | 0.81 | NOTUM (0.68) | NOTUMALDH1A1MAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206123-B2 | Prodrugs of inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. | 2015-12-08 | — | — | US | disclosed |
| US-20140128436-A1 | PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8609866-B2 | Prodrugs of inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2512466-A1 | PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN | Activesite Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152533-A1 | PRODRUGS OF INHIBITORS OF PLASMA KALLIKRIEN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075684-A1 | PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128436-A1 | PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | NOTUM 1127/4885ALDH1A1 1719/4885NR1H4 2422/4885 |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | NOTUM 4676/4885ALDH1A1 480/4885NR1H4 1110/4885 |
| US-20110152533-A1 | PRODRUGS OF INHIBITORS OF PLASMA KALLIKRIEN | KLKB1, KLK1, KLK5 | NOTUM 1201/4885ALDH1A1 1646/4885NR1H4 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.